Saeid Babaei, Ph.D., MBA, Chairman of the Board
Dr. Babaei has over 20 years of experience in leadership roles in the biopharmaceutical industry. He is currently Co-Founder, President, & CEO of AbCelex Technologies, a vaccine developing biotechnology company. Prior to AbCelex, Dr. Babaei has served as Vice President of Business Development at Aptose Biosciences Inc. (formerly known as Lorus Therapeutics Inc.) where he played a key role in a broad range of activities including establishing joint ventures, obtaining private financings, investor relations, and business development.
He successfully negotiated a partnership deal for Virulizin(R), a cancer immunotherapy product candidate to Zor Pharmaceuticals LLC ("ZOR"), a subsidiary of ZoticonBioventures Inc.
Previously, Dr. Babaei’s served as Director of Corporate Development at Northern Therapeutics Inc, a biopharmaceutical company which develops novel cell and gene therapies, where he was instrumental in launching the ‘first’ cell-based gene therapy clinical trial for patients with pulmonary arterial hypertension. He played key roles in obtaining financings, and in securing a partnership deal with United Therapeutics.
Dr. Babaei’s has served as President of AngioCell providing partnering support and advice to a range of clients on licensing, M&A, pipeline valuation, strategic planning and project financing.
Dr. Babaei obtained his MBA, and Ph.D. in Laboratory Medicine & Pathobiology from University of Toronto. He is Named author for several patents, sits on several charitable boards, has lectured around the world, and has been published well over 50 times.
Dr. Babaei enjoys weight lifting, travelling, and deep sea diving.
William V. Williams, MD, FRCP, President & CEO
Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 - 2016. There he facilitated entry of over 20 compounds into the clinic, including ruxolitinib (Jakafi), baricitinib, and epacadostat. He was responsible for establishing proof-of-concept in several therapeutic areas, and has been involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization in multiple therapeutic areas including oncology. This includes Jakafi for myelofibrosis and polycythemia vera and baricitinib for rheumatoid arthritis.
As Head of Experimental Medicine and VP of Clinical Pharmacology at GlaxoSmithKline, Dr. Williams evaluated several molecules in clinical studies in various therapeutic areas. He ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. He supported drug development programs with a wide range of clinical applications. The clinical pharmacology of lapatinib, an orally active drug for breast cancer and other solid tumors, was characterized under his supervision. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis.
Dr. Williams served as Head of Rheumatology Research at the University of Pennsylvania, ran a major research program in receptor biology, including developing bioactive peptides that mimicked granulocyte-macrophage colony-stimulating factor (GM-CSF), a known stimulant of the immune system. He collaborated with David B. Weiner, Ph.D., a well-known leader in immuno-oncology and vaccine research, in the development of DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma.
Dr. Williams earned his BSc. in Chemistry and Biotechnology from Massachusetts Institute of Technology and Medical Doctorate from Tufts University School of Medicine. Following his residency at the Boston VA Medical Center, Dr. Williams completed fellowship training in Rheumatology and Cellular Immunology at the University of Missouri. He then joined the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs.
Mr. Martin Schmieg, CPA, Director of the Board
Mr. Schmieg, with 35 years of business experience, is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries. As a hands-on leader, Mr. Schmieg’s early career focused on accounting and financial management responsibilities serving as Chief Financial Officer to privately held Cytometrics, Inc., Advanced Bionics Corporation and publicly traded Sirna Therapeutics, Inc. and Isolagen, Inc.
In 2006, Mr. Schmieg assumed the position of Chief Executive Office of Freedom-2, Inc., a venture startup in novel dermatology applications. While at Freedom-2, Mr. Schmieg raised $14 million in venture capital and led the company in the development and market introduction of InfinitInk®, which was a Time Magazine “Invention of the Year” in 2008. In 2009, Mr. Schmieg reversed merged Freedom-2 into Nuvilex, Inc., now PharmaCyte, Inc.
Since 2010, Mr. Schmieg has been providing strategic advisory services to the life sciences industry including engagements with the following companies: NeoStem, Inc. (now Caladrius Biosciences, Inc.), Beckman Coulter Genomics, Calimmune, Inc., Cryoport, Inc., Vetbiologics, a division of U.S. Stem Cell, Inc., Sapientia Pharmaceuticals, Inc. and Rokk3r Labs, LLC. Martin holds a BS from LaSalle University, Philadelphia, PA and is a certified public accountant.
Mr. Rahoul A. Sharan, CPA, Director of the Board
Rahoul Sharan is a Canadian Chartered Professional Accountant, whose career includes 25 years with public and private natural resource companies at both the management and board levels, concentrated in fund raising, mergers and acquisitions, regulatory compliance and financial reporting. He is President of KJN Management Ltd., a private corporation specializing in orchestrating and facilitating the IPO process for private natural resource companies, administrative, management and financial services.
He currently serves on the Board of Directors of Potash Ridge Corp., and has been on the Board of several public companies in the natural resource sector, including Titan Uranium Inc., Crescent Resources, Cue Resources, Ansell Capital Corp, Parallel Mining Corp, Global Copper Group Inc., One Voice Technologies, and Rainmaker Resources Ltd., playing an active role in strategic planning, corporate governance and business development.
Charles L. Wiseman, MD, FACP, Director of the Board, Co-Founder
Dr. Wiseman brings more than 40 years of academic and clinical experience to BriaCell Therapeutics Corp. As Co-Founder of BriaCell, he is the inventor for most of the Company’s intellectual property, and actively participates in its ongoing technology development.
During his career, Dr. Wiseman has managed numerous clinical development teams and programs, with a focus in oncology, tumor immunology, vaccine development, and genetics. He was previously the principal investigator for immunotherapy treatment protocols at the St. Vincent Cancer Treatment Center and the Los Angeles Oncologic Institute.
As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, Dr. Wiseman was one of the pioneers of the field of cancer vaccine therapeutics.
Dr. Wiseman is Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center. Dr. Wiseman has been cited in US News Top Doctors yearly since 2002.
Dr. Wiseman received his a B.S. at UCLA as Outstanding Student of Chemistry, and received his MD degree there also, serving as President of the Student American Medical Association.
Dr. Wiseman has written in over 100 peer reviewed publications and medical textbook chapters.